Alx Oncology Holdings Inc (NASDAQ: ALXO) on Friday, plunged -5.53% from the previous trading day, before settling in for the closing price of $0.75. Within the past 52 weeks, ALXO’s price has moved between $0.73 and $17.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -35.07% over the past five years. The company achieved an average annual earnings per share of 34.84%. With a float of $33.99 million, this company’s outstanding shares have now reached $53.05 million.
Let’s look at the performance matrix of the company that is accounted for 80 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Alx Oncology Holdings Inc (ALXO) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Alx Oncology Holdings Inc is 36.24%, while institutional ownership is 56.31%. The most recent insider transaction that took place on Feb 19 ’25, was worth 633. In this transaction SVP, FINANCE AND CAO of this company sold 550 shares at a rate of $1.15, taking the stock ownership to the 87,352 shares. Before that another transaction happened on Feb 19 ’25, when Company’s PRESIDENT & CSO sold 1,326 for $1.15, making the entire transaction worth $1,525. This insider now owns 579,388 shares in total.
Alx Oncology Holdings Inc (ALXO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.84% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.88% during the next five years compared to -32.29% drop over the previous five years of trading.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Trading Performance Indicators
Alx Oncology Holdings Inc (ALXO) is currently performing well based on its current performance indicators. A quick ratio of 7.26 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach -1.44 in one year’s time.
Technical Analysis of Alx Oncology Holdings Inc (ALXO)
Alx Oncology Holdings Inc (NASDAQ: ALXO) saw its 5-day average volume 0.51 million, a negative change from its year-to-date volume of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 6.79%. Additionally, its Average True Range was 0.11.
During the past 100 days, Alx Oncology Holdings Inc’s (ALXO) raw stochastic average was set at 1.97%, which indicates a significant decrease from 3.29% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 168.66% in the past 14 days, which was higher than the 114.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2183, while its 200-day Moving Average is $2.7028. Nevertheless, the first resistance level for the watch stands at $0.7506 in the near term. At $0.7940, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8293. If the price goes on to break the first support level at $0.6719, it is likely to go to the next support level at $0.6366. Assuming the price breaks the second support level, the third support level stands at $0.5932.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Key Stats
Market capitalization of the company is 37.75 million based on 53,384K outstanding shares. Right now, sales total 0 K and income totals -134,850 K. The company made 0 K in profit during its latest quarter, and -29,160 K in sales during its previous quarter.
